| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
31,901 |
2,556 |
$4.60M |
| A4657 |
Syringe, with or without needle, each |
1,527 |
770 |
$337K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
23,039 |
1,959 |
$88K |
| J1756 |
Injection, iron sucrose, 1 mg |
5,678 |
1,437 |
$29K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
24,618 |
1,867 |
$24K |
| 82728 |
|
300 |
236 |
$3K |
| 90662 |
|
85 |
78 |
$2K |
| G0008 |
Administration of influenza virus vaccine |
44 |
44 |
$2K |
| 90674 |
|
37 |
36 |
$826.79 |
| 85041 |
|
660 |
553 |
$0.00 |
| 83970 |
|
563 |
479 |
$0.00 |
| 85048 |
|
656 |
551 |
$0.00 |
| 83540 |
|
411 |
326 |
$0.00 |
| 82108 |
|
46 |
40 |
$0.00 |
| 0634 |
|
449 |
33 |
$0.00 |
| 83550 |
|
385 |
301 |
$0.00 |
| 0636 |
|
411 |
34 |
$0.00 |
| 0270 |
|
26 |
15 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
19 |
16 |
$0.00 |
| 0305 |
|
34 |
14 |
$0.00 |
| 0301 |
|
38 |
13 |
$0.00 |